Adalimumab for the treatment of psoriasis

Psoriasis is a debilitating skin disorder that affects 2% of the Caucasian population. In those with moderate-to-severe disease, treatment is challenging, with many cases ultimately proving refractory to traditional systemic therapies, such as methotrexate. For this group of patients, biologic therapies have emerged as novel, targeted approaches for management. One of these, the anti-TNF-α inhibitor adalimumab, is the focus of this article, with emphasis on its pharmacology, clinical efficacy and safety profile.